Evidence map›Paper›PMID 33928205›Full record

ArticleJournal of the Endocrine Society2021

Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor.

Constance L Chik, Frank K H van Landeghem, Jacob C Easaw, Vivek Mehta

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the Endocrine Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Targeted therapy of papillary craniopharyngioma.Medical oncology (Northwood, London, England) · 2025
    Review
  6. Article
  7. Targeted treatment for craniopharyngioma.Journal of neuro-oncology · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Pituitary Tumorigenesis-Implications for Management.Medicina (Kaunas, Lithuania) · 2023
    Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Constance L ChikDivision of Endocrinology and Metabolism, Department of Medicine, University of Alberta, Edmonton, AB T6G 2G3, Canada.ORCID https://orcid.org/0000-0001-9609-0896
Frank K H van LandeghemDepartment of Laboratory Medicine & Pathology, University of Alberta, Walter Mackenzie Health Sciences Centre, Edmonton, AB T6G 2B7, Canada.
Jacob C EasawCross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Vivek MehtaDivision of Neurosurgery, Department of Surgery, University of Alberta, Walter Mackenzie Health Sciences Centre, Edmonton, AB T6G 2B7, Canada.
University of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The papillary subtype of craniopharyngioma (CP) rarely occurs in children and commonly presents as a suprasellar lesion. Patients with papillary CPs frequently harbor the

Indexed as

BRAF mutationpapillary craniopharyngiomavemurafenib

Identifiers

PMID33928205
PMCPMC8064044
OpenAlexW3137503433

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.